TY - JOUR
T1 - A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research
AU - Amaral, Teresa
AU - Nanz, Lena
AU - Higuita, Lina Maria Serna
AU - Ascierto, Paolo
AU - Berking, Carola
AU - Couselo, Eva Muñoz
AU - Donia, Marco
AU - Dummer, Reinhard
AU - Gutzmer, Ralf
AU - Haushild, Axel
AU - Jalving, Mathilde
AU - Lee, Rebecca
AU - Lorigan, Paul
AU - Marquez-Rodas, Ivan
AU - Michelin, Olivier
AU - Nathan, Paul
AU - Robert, Caroline
AU - Schadendorf, Dirk
AU - Sobczuk, Pawel
AU - Flatz, Lukas
AU - Leiter, Ulrike
AU - Garbe, Claus
N1 - Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.
PY - 2025/1/17
Y1 - 2025/1/17
N2 - BACKGROUND: Over the past decade, PD-1-based immune checkpoint inhibitors (ICI) and targeted therapies (TT) with BRAF and MEK inhibitors transformed melanoma treatment. Both are widely used in the adjuvant setting. However, for patients with a BRAF V600 mutation, the optimal adjuvant therapy remains unclear due to the lack of head-to-head comparison studies.METHODS: We conducted a systematic review of real-world data on adjuvant therapy in stage III melanoma to determine the best option for patients with BRAF V600 mutations. Kaplan-Meier curves were generated for TT and ICI using Digitizelt software.RESULTS: Nine publications with 3625 patients were included. TT showed better relapse-free survival (RFS) at 6, 12, 24, and 36 months than ICI. A similar trend was observed for distant metastasis-free survival (DMFS), with no apparent difference in overall survival.CONCLUSION: Real-world data suggest that adjuvant TT may be associated with better RFS and DMFS in stage III BRAF V600-mutated melanoma compared to ICI.
AB - BACKGROUND: Over the past decade, PD-1-based immune checkpoint inhibitors (ICI) and targeted therapies (TT) with BRAF and MEK inhibitors transformed melanoma treatment. Both are widely used in the adjuvant setting. However, for patients with a BRAF V600 mutation, the optimal adjuvant therapy remains unclear due to the lack of head-to-head comparison studies.METHODS: We conducted a systematic review of real-world data on adjuvant therapy in stage III melanoma to determine the best option for patients with BRAF V600 mutations. Kaplan-Meier curves were generated for TT and ICI using Digitizelt software.RESULTS: Nine publications with 3625 patients were included. TT showed better relapse-free survival (RFS) at 6, 12, 24, and 36 months than ICI. A similar trend was observed for distant metastasis-free survival (DMFS), with no apparent difference in overall survival.CONCLUSION: Real-world data suggest that adjuvant TT may be associated with better RFS and DMFS in stage III BRAF V600-mutated melanoma compared to ICI.
KW - Humans
KW - Melanoma/genetics
KW - Proto-Oncogene Proteins B-raf/genetics
KW - Chemotherapy, Adjuvant
KW - Mutation
KW - Immune Checkpoint Inhibitors/therapeutic use
KW - Neoplasm Staging
KW - Skin Neoplasms/genetics
KW - Protein Kinase Inhibitors/therapeutic use
KW - Molecular Targeted Therapy
UR - http://www.scopus.com/inward/record.url?scp=85211748987&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2024.115160
DO - 10.1016/j.ejca.2024.115160
M3 - Journal article
C2 - 39673834
SN - 0959-8049
VL - 215
SP - 115160
JO - European journal of cancer (Oxford, England : 1990)
JF - European journal of cancer (Oxford, England : 1990)
M1 - 115160
ER -